Get started
Author

Lisa T. Dooley

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
2008 · Craig L Leonardi, Alexa B Kimball, et al. · The Lancet · 1,877
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
2008 · Kim A Papp, Richard G Langley, et al. · The Lancet · 1,367
Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial
2005 · Kristian Reich, Frank O Nestle, et al. · The Lancet · 1,045
Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis
2010 · Christopher E.M. Griffiths, Bruce E. Strober, et al. · New England Journal of Medicine · 860
A Human Interleukin-12/23 Monoclonal Antibody for the Treatment of Psoriasis
2007 · Gerald G. Krueger, Richard G. Langley, et al. · New England Journal of Medicine · 809
PDF
Infliximab induction therapy for patients with severe plaque-type psoriasis: A randomized, double-blind, placebo-controlled trial
2004 · Alice B. Gottlieb, Robert Evans, et al. · Journal of the American Academy of Dermatology · 578
A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis
2006 · Alan Menter, Steven R. Feldman, et al. · Journal of the American Academy of Dermatology · 514
Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: Results from the induction and maintenance psoriatic arthritis clinical trial 2
2007 · D. van der Heijde, A. Kavanaugh, et al. · Arthritis & Rheumatism · 182
Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis
2003 · Alice B. Gottlieb, Umesh Chaudhari, et al. · Journal of the American Academy of Dermatology · 156
Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-α monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris
2003 · Alice B. Gottlieb, Salman Masuda, et al. · Journal of the American Academy of Dermatology · 153
Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial
2006 · K. Reich, F.O. Nestle, et al. · British Journal of Dermatology · 131
Infliximab improves health-related quality of life in the presence of comorbidities among patients with moderate-to-severe psoriasis
2008 · S.R. Feldman, A.B. Gottlieb, et al. · British Journal of Dermatology · 87
The National Psoriasis Foundation Psoriasis Score (NPF-PS) system versus the Psoriasis Area Severity Index (PASI) and Physician's Global Assessment (PGA): a comparison.
2003 · Alice B Gottlieb, Umesh Chaudhari, et al. · PubMed · 87
Infliximab treatment improves productivity among patients with moderate-to-severe psoriasis.
2007 · Kristian Reich, Frank O Nestle, et al. · PubMed · 33
Treatment with infliximab is associated with "Major clinical response" in psoriatic arthritis patients treated with infliximab: Analysis of two double-blind placebo controlled trials.
2005 · Kavanaugh, A, Krueger, GG, et al. · Document Server@UHasselt (UHasselt) · 3
Şiddetli plak tipi psoriazisde infliksimab indüksiyon tedavisi: Randomize, çift-kör, plasebo kontrollü çalışma
2004 · Alice B. Gottlieb, Robert J. Evans, et al. · Journal of the American Academy of Dermatology · 1
Works count: 17
Citation count: 7,883
H-index: 14
I10-index: 14
Year
Topic
Type